Sun Yat-sen Memorial Hospital Of Sun Yat-sen University

This study is testing if adding an immunotherapy drug (tirellizumab) to standard chemotherapy before surgery works better than surgery alone for early-stage oral cancer. It will involve 60 patients who are randomly assigned to receive either the new drug combination followed by s…

This study is testing whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery works better for treating locally advanced cervical cancer. About 54 participants will receive the drug combination for three cycles, followed by surgery. Researche…

This study is testing if adding a targeted drug called pyrotinib to standard chemotherapy before surgery works better than chemotherapy alone for people with a specific, high-risk type of early breast cancer. It will involve about 160 adults with hormone-positive, HER2-low breast…

This study is testing if adding an oral drug called pyrotinib to standard chemotherapy before surgery is more effective for a specific type of breast cancer. It involves 140 women with stage II-III, hormone-positive, HER2-negative breast cancer that has high levels of a protein c…

This study compares a new approach using two targeted oral medications against standard chemotherapy for advanced breast cancer that has specific genetic features. After initial chemotherapy, half the participants switch to the targeted drug combination as long-term maintenance t…

This study is testing whether a combination of two drugs (trastuzumab and a taxane chemotherapy) given before surgery can effectively shrink tumors in people with a specific type of early breast cancer (HER2-positive). The main goal is to see if this approach allows more patients…

This study is testing whether a form of vitamin B12 (mecobalamin) can prevent a painful skin reaction on the hands and feet caused by a common breast cancer drug, capecitabine. About 234 women with early breast cancer will be randomly assigned to receive either the vitamin B12 tr…